Kisspeptin-10 vs Kisspeptin-54

How they're alike

Kisspeptin-10 (KP-10) and kisspeptin-54 (KP-54) are both products of the KISS1 gene and both act as full agonists at the kisspeptin receptor KISS1R, previously called GPR54 (Kotani 2001; Kirby 2010). They share the conserved C-terminal RF-amide pharmacophore — the decapeptide YNWNSFGLRF-NH2 that BLAST-aligns at 100% identity over the last 10 residues of KP-54 — and this shared motif is considered the minimally active receptor-binding region of the kisspeptin family (Kotani 2001). Functionally, both peptides stimulate the hypothalamic–pituitary–gonadal (HPG) axis by activating KISS1R on GnRH neurons in the hypothalamus, driving GnRH release and downstream LH and FSH secretion (Gottsch 2004; Dhillo 2005; Xie 2022). Both have been investigated as research-only tools for probing reproductive neuroendocrine physiology, and neither has FDA or EMA approval for any indication. Both have also been examined outside reproduction for class-level effects on glucose homeostasis, where the kisspeptin signal cuts across isoforms (Izzi-Engbeaya 2019).

How they differ

The most consequential difference is pharmacological duration and downstream potency in vivo. KP-54 carries an extended N-terminal sequence upstream of the shared RF-amide core, and this extension has been associated with a more potent in vivo effect compared with KP-10, with one mechanistic study attributing the gap to differences in receptor internalisation and signal duration rather than to acute binding affinity at KISS1R (PLOS ONE 2017 In the side-by-side mouse work from Gottsch and colleagues (2004), both KP-54 and KP-10 stimulated gonadotropin secretion after intracerebroventricular administration, but the kinetics and magnitude of LH responses differ between the two forms.

The clinical translation has followed those pharmacological differences. KP-54 has been the form carried into fertility medicine: a single subcutaneous KP-54 injection acutely raises LH and increases LH pulsatility in healthy women (Jayasena 2013), KP-54 triggers oocyte maturation in IVF (Jayasena 2014), and a randomised Phase 2 trial showed that a second KP-54 dose improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (Abbara 2017; see also the JCEM 2015 OHSS report at KP-54 has also been deployed as a diagnostic probe: it accurately identifies hypothalamic GnRH neuronal dysfunction in men with congenital hypogonadotropic hypogonadism (Abbara 2021), and chronic SC infusion stimulates gonadotropin release in women in a manner that correlates with basal oestradiol (Narayanaswamy 2016). KP-10, by contrast, has been characterised mainly as a shorter-acting mechanistic stimulus: it is a potent stimulator of LH and increases LH pulse frequency in men (George 2011), and its reproductive-hormone effects show sexual dimorphism in humans (Jayasena 2011). Where KP-54 is durable enough for SC injection regimens, KP-10's short plasma half-life of about 4–5 minutes constrains it to IV infusion or bolus designs in the available human studies.

Head-to-head clinical evidence

A direct human head-to-head exists. Jayasena and colleagues reported an intravenous head-to-head of kisspeptin-10, kisspeptin-54 and GnRH for gonadotrophin secretion in healthy men, providing a within-subject pharmacological comparison of the two isoforms against the downstream releasing hormone (Human Reproduction Beyond that, the most direct cross-isoform mechanistic paper compares the two peptides in vivo and concludes that KP-54 is the more potent of the pair, with the difference attributed to longer-lasting receptor engagement rather than to acute receptor affinity (PLOS ONE 2017 Animal work from Gottsch and colleagues (2004) provided one of the earliest side-by-side ICV administrations of KP-54 and KP-10 and showed both peptides drive gonadotropin secretion in the mouse. No Phase 3 head-to-head trial of KP-10 versus KP-54 in any clinical indication is present in the available dossier.

Safety profile comparison

The two isoforms share the same receptor and the same downstream reproductive endocrinology, so the broad class signals overlap. Both have been administered to humans in short, supervised research protocols without serious adverse events being reported in the underlying papers in this dossier (Dhillo 2005; George 2011). For KP-54, chronic subcutaneous administration in adult male rats produced testicular degeneration (Thompson 2006), and a related study reported testicular degeneration with high-dose acute KP-54 via a central mechanism (Thompson 2009) — these are class-relevant signals tied to sustained HPG-axis over-stimulation in animal models. On the human side, chronic KP-54 exposure in women with hypothalamic amenorrhea produced tachyphylaxis (Jayasena 2009), while twice-daily SC KP-54 did not abolish menstrual cyclicity in healthy women (Jayasena 2013, JCEM). The KP-10 safety record in the dossier is narrower and reflects acute IV exposure in mechanistic studies rather than chronic dosing. Neither isoform has a long-term human safety profile in the available literature.

Indication overview

Neither kisspeptin-10 nor kisspeptin-54 has FDA or EMA approval for any indication; both are research-stage peptides. The clinical pipeline activity in the dossier is concentrated on kisspeptin-54, where a Phase 2 randomised controlled trial has examined a second-dose KP-54 strategy for oocyte maturation in women at high risk of OHSS during IVF (Abbara 2017), and KP-54 has been used as a hypothalamic-function probe in congenital hypogonadotropic hypogonadism (Abbara 2021). Kisspeptin-10 has been studied mechanistically as a stimulator of LH and LH pulse frequency in men (George 2011) and for its sexually dimorphic effects on reproductive hormones in healthy adults (Jayasena 2011). Beyond reproduction, the class has been examined for a role in glucose homeostasis, with the available evidence cutting across isoforms rather than singling out KP-10 or KP-54 (Izzi-Engbeaya 2019). Statements about specific approved indications, brand names, or established treatment roles do not apply to either peptide at this time.